Sign In

Login

Password

Forgot Password ? Sign Up

Apremilast (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Apremilast" in Vietnamese language version.

refsWebsite
Global rank Vietnamese rank
8nih.gov
4th place
7th place
5doi.org
2nd place
2nd place
5web.archive.org
1st place
1st place
1medscape.com
719th place
1,344th place
1adooq.com
low place
low place
1celgene.com
low place
low place
1fda.gov
447th place
625th place
1rheumatology.org
low place
low place
1otezla.com
low place
low place
1celgenecanada.net
low place
low place
1europa.eu
68th place
114th place
1uaeh.edu.mx
low place
low place
1utopharm.com
low place
low place

adooq.com

celgene.com

ir.celgene.com

celgenecanada.net

doi.org

  • Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S (tháng 3 năm 2015). "Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis". J. Rheumatol. Quyển 42 số 3. tr. 479–88. doi:10.3899/jrheum.140647. PMID 25593233.
  • Mease, PJ; Armstrong, AW (ngày 25 tháng 2 năm 2014). "Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis". Drugs. Quyển 74 số 4. tr. 423–41. doi:10.1007/s40265-014-0191-y. PMC 3958815. PMID 24566842.
  • Kragstrup, TW; Adams, M; Lomholt, S; Nielsen, MA; Heftdal, LD; Schafer, P; Deleuran, B (2019). "IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis". Ther Adv Musculoskelet Dis. Quyển 11. tr. 1759720X19828669. doi:10.1177/1759720X19828669. PMC 6391542. PMID 30833991.
  • Schafer, Peter (ngày 1 tháng 6 năm 2012). "Apremilast mechanism of action and application to psoriasis and psoriatic arthritis". Biochemical Pharmacology. Quyển 83 số 12. tr. 1583–1590. doi:10.1016/j.bcp.2012.01.001.
  • Schafer, PH; Parton, A; Gandhi, AK; Capone, L; Adams, M; Wu, L; Bartlett, JB; Loveland, MA; Gilhar, A (ngày 1 tháng 2 năm 2010). "Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis". British Journal of Pharmacology. Quyển 159 số 4. tr. 842–855. doi:10.1111/j.1476-5381.2009.00559.x. PMC 2829210. PMID 20050849.

europa.eu

ema.europa.eu

fda.gov

medscape.com

reference.medscape.com

  • "Otezla (aprelimast) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Truy cập ngày 28 tháng 3 năm 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S (tháng 3 năm 2015). "Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis". J. Rheumatol. Quyển 42 số 3. tr. 479–88. doi:10.3899/jrheum.140647. PMID 25593233.
  • Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC (tháng 2 năm 2018). "Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL". J Drugs Dermatol. Quyển 17 số 2. tr. 221–228. PMID 29462231.
  • Mease, PJ; Armstrong, AW (ngày 25 tháng 2 năm 2014). "Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis". Drugs. Quyển 74 số 4. tr. 423–41. doi:10.1007/s40265-014-0191-y. PMC 3958815. PMID 24566842.
  • Kragstrup, TW; Adams, M; Lomholt, S; Nielsen, MA; Heftdal, LD; Schafer, P; Deleuran, B (2019). "IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis". Ther Adv Musculoskelet Dis. Quyển 11. tr. 1759720X19828669. doi:10.1177/1759720X19828669. PMC 6391542. PMID 30833991.
  • Schafer, PH; Parton, A; Gandhi, AK; Capone, L; Adams, M; Wu, L; Bartlett, JB; Loveland, MA; Gilhar, A (ngày 1 tháng 2 năm 2010). "Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis". British Journal of Pharmacology. Quyển 159 số 4. tr. 842–855. doi:10.1111/j.1476-5381.2009.00559.x. PMC 2829210. PMID 20050849.

ncbi.nlm.nih.gov

  • Mease, PJ; Armstrong, AW (ngày 25 tháng 2 năm 2014). "Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis". Drugs. Quyển 74 số 4. tr. 423–41. doi:10.1007/s40265-014-0191-y. PMC 3958815. PMID 24566842.
  • Kragstrup, TW; Adams, M; Lomholt, S; Nielsen, MA; Heftdal, LD; Schafer, P; Deleuran, B (2019). "IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis". Ther Adv Musculoskelet Dis. Quyển 11. tr. 1759720X19828669. doi:10.1177/1759720X19828669. PMC 6391542. PMID 30833991.
  • Schafer, PH; Parton, A; Gandhi, AK; Capone, L; Adams, M; Wu, L; Bartlett, JB; Loveland, MA; Gilhar, A (ngày 1 tháng 2 năm 2010). "Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis". British Journal of Pharmacology. Quyển 159 số 4. tr. 842–855. doi:10.1111/j.1476-5381.2009.00559.x. PMC 2829210. PMID 20050849.

otezla.com

rheumatology.org

uaeh.edu.mx

utopharm.com

web.archive.org